A Leading Developer of Allogeneic Cellular Therapies

Nohla is the leading developer of allogeneic cellular therapies for patients with hematologic malignances and other critical diseases. These differentiated product candidates are available off the shelf without the need for HLA matching. The company’s lead product, NLA101, is a hematopoietic cell graft consisting of ex vivo expanded CD34+ stem and progenitor cells derived from umbilical cord blood. Clinical results to date demonstrate that NLA101 provides rapid hematopoietic recovery, especially functional myelopoiesis for the prevention of infection.

Management Team

Nohla’s Management Team is comprised of life science leaders and innovators with significant clinical and operational expertise — Fred Hutch, AstraZeneca, ICOS, Juno, CellPro, ZymoGenetics to name a few. As a result, we are well-positioned to achieve our near- and long-term objectives and continue to advance Nohla’s lead clinical program that could provide life-changing treatments for patients in need.

Kathleen Fanning

President and Chief Executive Officer

Kathleen Fanning is the President and Chief Executive Officer of Nohla Therapeutics. Ms. Fanning has over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies, most recently serving as Chief Operating Officer at VentiRx Pharmaceuticals. During her tenure at VentiRx, she led strategic planning activities and corporate and business development. She played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation. Prior to joining VentiRx, Ms. Fanning held senior leadership roles at Cell Therapeutics Inc., as Vice President of Acquisitions and Vice President of Sales and Marketing, with responsibilities that included building and managing the company’s first global sales and marketing organization. She also served as Senior Director of Sales and Marketing at CellPro, Inc. and spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca), with increasing roles of responsibility including Director of Marketing for Oncology Products, where she led the successful U.S. launch of Arimidex®. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio.

Colleen Delaney, MD

Chief Medical Officer

Colleen Delaney is the Chief Medical Officer at Nohla Therapeutics. She is also an Associate Member and recipient of the Madeline Dabney Adams Endowed Chair of the Fred Hutch Clinical Research Division and an Associate Professor at the UW Department of Pediatrics, Division of Pediatric Hematology/Oncology. Colleen is a member on the Advisory Council on Blood Stem Cell Transplantation of the Health Resources and Services Administration. She also serves on the Boards of Directors of the American Society of Bone Marrow Transplant and the Cord Blood Association.

In 2006, she established and became the Director of the Cord Blood Transplant Program at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, which has grown to be one of the busiest such programs in the country and the coordinating center of several multicenter clinical trials. She is the sponsor-investigator of three Investigational New Drug FDA files and has been the Principal Investigator of nine ongoing and completed clinical trials and several ancillary studies.

Colleen is also the Principal Investigator of a research laboratory focused on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group at Fred Hutchinson Cancer Research Center developed novel and clinically feasible methods for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off the shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Colleen received her MD from Harvard Medical School in 1996, and went on to complete a residency in Pediatrics at the University of California, San Francisco followed by a Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center/University of Washington.

Shelly Heimfeld, PhD

Advisory Board Chair and Executive Vice President, Manufacturing and Research

Shelly Heimfeld is a Full Faculty Member at Fred Hutchinson Cancer Research Center and serves as Scientific Laboratory Director for the cGTP Cellular Therapy Laboratory and cGMP Therapeutic Manufacturing Facilities. These facilities are responsible for all minimally and more extensively manipulated cell components used for treatment of patients at the Center. His primary responsibilities are to ensure the safety, quality, and effectiveness of each product, but also include implementation of new technologies, translation of basic science procedures into appropriate clinical protocols, product development, process improvement, and regulatory compliance.

Shelly is internationally recognized for his research in hematopoietic-derived stem cells and the development of cell processing technologies for improved cancer therapy. His long-term goals have a direct therapeutic focus, many involving the “engineering” of transplant products to improve clinical outcomes. Pre-clinical translation activities include identification of better markers for characterization of hematopoietic stem and progenitor cells, improvements in isolation/purification technologies, and development of ex vivo manipulation strategies that can enhance the therapeutic potential of cells such as T-cell-based immunotherapy for treatment of various diseases.

Shelly is a Past-President for International Society of Cellular Therapy (ISCT), and is a leading authority in the FDA regulations and lab practices needed for clinical cell therapies, including Good Laboratory Practice (GLP), Good Tissue Practice (GTP), and Good Manufacturing Practice (GMP). Shelly continues to work with the FDA and other organizations to facilitate the exchange of ideas and best practices in the rapidly evolving area of Cell Therapy.

Shelly received his PhD in Cell Differentiation from the University of California, Irvine and completed postdoctoral studies with Dr. Irving Weissman at Stanford before going into industry to work as a founding scientist at SyStemix and later at CellPro, Inc., the first company to develop an FDA-approved device for CD34+ cell enrichment.

Tom Swallow

Vice President, Finance & Administration

Tom Swallow is the Vice President of Finance and Administration at Nohla. Mr. Swallow has over 30 years of finance and accounting experience at both public and private companies. In his previous role, Mr. Swallow served as Vice President, Finance at VentiRx since 2011. Before joining VentiRx, Mr. Swallow served as Senior Director, Finance for Calistoga Pharmaceuticals, a privately held biotechnology company developing innovative therapeutics for patients with cancer or inflammatory diseases (Calistoga was acquired by Gilead in April 2011). At Calistoga, Mr. Swallow was responsible for managing finance and accounting operations and financial system implementation. Prior to Calistoga, Mr. Swallow worked at ICOS, a public biotechnology company engaged in the discovery and development of product candidates for the treatment of serious medical diseases, where he held the position of Controller and then Director of Finance. Mr. Swallow worked at ICOS from its inception through its acquisition by Eli Lily in January 2007. During his tenure at ICOS, Mr. Swallow was responsible for SEC reporting, investment management, and financial planning and analysis. Mr. Swallow also worked as Senior Director, Finance for Targeted Genetics and as an Accounting Manager for Maryatt Industries. Mr. Swallow holds a B.S. in Accounting from Central Washington University.

Mark Gauthier

Vice President, Regulatory Affairs & Quality

Mark Gauthier, Vice President of Regulatory Affairs & Quality, has over 40 years of experience in drug development. He began his career in pre-clinical research, ultimately found his niche in regulatory affairs and has served in increasingly responsible roles in that capacity at The Upjohn Company, Immunex, ZymoGenetics, Acucela and CTI BioPharma, prior to joining Nohla Therapeutics. His extensive history of FDA and EMA interaction combined with a scientific background culminates in an experience base that includes working with recombinant proteins, small molecules, and regenerative medicine products. Mr. Gauthier has shepherded a supplemental NDA for hormone refractory prostate cancer, 2 new NDAs for multiple sclerosis and myelofibrosis products, and a BLA for hemostasis through the FDA review and approval process. In addition, he has been the regulatory manager for numerous active INDs for products being developed for AIDS, cancer, and hemostasis, among others.

Jim DeNike

Senior Director, Corporate Development & Investor Relations

Jim DeNike is the Senior Director of Corporate Development & Investor Relations at Nohla. In this role, Mr. DeNike oversees corporate-wide internal and external communications and is the primary contact for the investment community. Throughout his 25-year career in communications and investor relations working for both public and private companies, Mr. DeNike has provided strategic oversight on matters affecting corporate visibility and reputation. Prior to Nohla, he served since 2013 as the Senior Director, Corporate Communications and Investor Relations at OncoGenex Pharmaceuticals, Inc., a public company developing therapeutics addressing treatment resistance in cancer. Before joining OncoGenex, Mr. DeNike served as the Senior Director, Corporate Communications & Investor Relations for Trubion since 2006, and continued to serve as the Senior Director of Corporate Affairs following Trubion’s acquisition by Emergent BioSolutions. Prior to Trubion, Mr. DeNike created and led the role of corporate communications and investor relations for Corixa, a Seattle-based immunotherapy company. In addition to his extensive experience in life sciences, Mr. DeNike began his career working for leading technology PR agencies supporting clients such as Microsoft, HP, 3com and Polycom. Mr. DeNike holds a B.S. in Public Relations from San Jose State University.

Esther Cuno

Director, Human Resources

Esther Cuno has over ten years of experience in global human resources in non-profit and for-profit sectors spanning life science, healthcare, and retail industries. Having most recently served as Director of Recruiting for Fred Hutchinson Cancer Research Center, Ms. Cuno also previously held positions at Safeway, Inc. and Starbucks Corporation. Prior to Human Resources, she worked in the legal industry for eight years. Ms. Cuno has a Bachelor of Science in Sociology from Oregon State University; she also earned her Senior and Global Professional in Human Resources certifications with the Human Resources Certification Institute and is a Senior Certified Professional with the Society for Human Resource Management.

Directors

Our Board of Directors includes life science leaders and investors with a long-standing track record of success and strategic guidance.

Steven Gillis, PhD

Chairman

Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. GlaxoSmithKline acquired Corixa Corporation in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. He currently serves as a director or Chairman of multiple private and public biotechnology companies in the United States.

Brian Daniels, MD

Non-Executive Director

Brian has twenty years of experience in clinical development, medical affairs, and commercialization. Amongst Brian’s accomplishments was directing the drug development efforts at Bristol-­Myers Squibb Company (BMS). His efforts led to the registration of numerous innovative medicines for the treatment of cancer, HIV, viral hepatitis, depression, rheumatoid arthritis, diabetes, cardiovascular disorders, and rare genetic disorders. More than ten of these medicines achieved greater than $1billion annual sales. He was also responsible for communicating the value of these medicines to payers and ensuring their safe and appropriate use.

Through July 2014, Dr. Brian Daniels served as Senior Vice President, Global Development and Medical Affairs, and a member of the Senior Management Team, at BMS. Brian’s contributions at BMS were exceptional and, as a consequence, he has earned an unparalleled reputation across the industry. He also has prior Development experience at both Merck and Genentech.

Brian’s areas of expertise include all aspects of R&D in biopharma (from Research to Development organization, process and portfolio topics). He also has deep expertise in Medical Affairs and clinical operations.

Brian has built a network of relationships within both biopharma and the VC community, he has a track record of developing and launching new drugs across both primary and specialty care (he led one of the most productive Development organizations across the entire biopharma industry in the last decade), and he is highly recognized among the scientific community.

In addition to his role as a Senior Advisor with BCG, Brian now serves as a Venture Partner at 5am Ventures in Menlo Park, California and volunteers at The Gladstone Institutes at the University of California in San Francisco as a translational partner.

He is a member of the Board for Novo Nordisk A/S.

In 2006, she established and became the Director of the Cord Blood Transplant Program at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, which has grown to be one of the busiest such programs in the country and the coordinating center of several multicenter clinical trials. She is the sponsor-investigator of three Investigational New Drug FDA files and has been the Principal Investigator of nine ongoing and completed clinical trials and several ancillary studies.

Colleen is also the Principal Investigator of a research laboratory focused on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group at Fred Hutchinson Cancer Research Center developed novel and clinically feasible methods for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off the shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Colleen received her MD from Harvard Medical School in 1996, and went on to complete a residency in Pediatrics at the University of California, San Francisco followed by a Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center/University of Washington.

Lawrence Gozlan

Non-Executive Director

Lawrence Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities.

Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte.

Lawrence currently serves as a Director on the Board of Prana Biotechnology (NASDAQ: PRAN). He holds a Bachelor of Science with Honours in immunology from the University of Melbourne.

Michael Sistenich

Non-Executive Director

Michael Sistenich has over 18 years’ experience in senior leadership roles in the life sciences industry as an investor, advisor, and investment banker. Most recently, Michael served as Interim Chief Executive Officer of Nohla Therapeutics, Inc., during which time he successfully spearheaded its startup and guided its transformational Series A financing in November 2016. He was the Director and Head of life sciences investment banking at Bell Potter Securities from June 2014 until he joined Nohla. Prior to Bell Potter, he was the Founder and Senior Portfolio manager of the Meditor Cobra fund, a EUR 500mn Healthcare Hedge fund based in London. From 1997 to 2003, Michael served as Director and Global Head of Healthcare at DWS Investments, Deutsche Bank, overseeing EUR 6bn of direct investments in the public and private markets. Michael holds an M.Sc in Biochemistry from the University of Oxford, UK.

Kathleen Fanning

President and Chief Executive Officer

Kathleen Fanning is the President and Chief Executive Officer of Nohla Therapeutics. Ms. Fanning has over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies, most recently serving as Chief Operating Officer at VentiRx Pharmaceuticals. During her tenure at VentiRx, she led strategic planning activities and corporate and business development. She played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation. Prior to joining VentiRx, Ms. Fanning held senior leadership roles at Cell Therapeutics Inc., as Vice President of Acquisitions and Vice President of Sales and Marketing, with responsibilities that included building and managing the company’s first global sales and marketing organization. She also served as Senior Director of Sales and Marketing at CellPro, Inc. and spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca), with increasing roles of responsibility including Director of Marketing for Oncology Products, where she led the successful U.S. launch of Arimidex®. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio.